Affymetrix -neue Produkteinführung! - 500 Beiträge pro Seite

[trade1]

Affymetrix Launches GeneChip(R) Arabidopsis Genome Array

SANTA CLARA, Calif., July 31 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX) announced today that it has launched its first GeneChip(R) expression analysis product for agricultural research, the Arabidopsis Genome Array. Arabidopsis is the most common model system used by plant biology researchers worldwide. The Arabidopsis Genome Array is the result of a joint effort between Affymetrix and the Novartis Agricultural Discovery Institute, Inc. (NADII) to evolve a former custom GeneChip(R) array designed for NADII into a commercially-available, standard GeneChip product. This product offering analyzes the expression of over 8,000 "Arabidopsis thaliana" gene sequences derived from the GenBank database, the government repository of all publicly available DNA sequences.

"Cutting edge agricultural research is essential to sustain and support crops for the growing population of the world in an environmentally responsible fashion. We are pleased to offer this powerful new product to all of our customers engaged in agriculture research, through a fruitful collaboration with NADII, a clear leader in the field," commented Susan E. Siegel, President of Affymetrix. "Arabidopsis is an excellent model system for many crop species, which our customers can study with custom GeneChip arrays or by making their own arrays using our integrated spotted array systems."

"The Arabidopsis array has been used widely throughout the NADII organization as an important tool for agricultural research and we expect that its broader availability will accelerate and help standardize plant and agricultural research worldwide," stated Steven Briggs, President and Chief Executive Officer of the Novartis Agricultural Discovery Institute. "We are delighted that we can contribute to the global community through our collaboration with Affymetrix, the microarray market leader."

This new product joins a GeneChip product portfolio that includes human, rat, murine, yeast and E. coli genome expression analysis arrays; Rat Neurobiology, Rat Toxicology and Human Cancer Biology directed expression analysis arrays; as well as custom expression analysis arrays, the GenFlex(TM) Tag array, genotyping products and disease management products. Affymetrix also offers an easy to use, do-it-yourself spotted array platform for study of organisms that have not yet been sequenced.

Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company`s GeneChip(R) system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner, and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company`s spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com

All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Annual Report on Form 10-K for the year ended December 31, 1999 and Affymetrix` other SEC reports, including its Quarterly Reports on Form 10-Q for quarterly subsequent periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc. SOURCE Affymetrix, Inc.


CONTACT: Edward M. Hurwitz, Vice President and Chief Financial Officer, 408-731-5000, or Anne Bowdidge, Director of Investor Relations, 408-731-5925, both of Affymetrix, Inc./

[humm]

@trade1:
danke für die infos .
warum neuen thread?
es macht alles unübersichtlich....